Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $1.0 million.

  • Exagen's Change in Account Payables rose 18543.05% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 43228.2%. This contributed to the annual value of $308000.0 for FY2024, which is 35970.15% up from last year.
  • Latest data reveals that Exagen reported Change in Account Payables of $1.0 million as of Q3 2025, which was up 18543.05% from -$1.8 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Change in Account Payables peaked at $2.3 million during Q4 2024, and registered a low of -$1.8 million during Q2 2025.
  • For the 5-year period, Exagen's Change in Account Payables averaged around $4000.0, with its median value being $231000.0 (2025).
  • As far as peak fluctuations go, Exagen's Change in Account Payables skyrocketed by 103062.5% in 2023, and later tumbled by 46829.27% in 2024.
  • Quarter analysis of 5 years shows Exagen's Change in Account Payables stood at $430000.0 in 2021, then plummeted by 137.21% to -$160000.0 in 2022, then surged by 1030.62% to $1.5 million in 2023, then surged by 56.88% to $2.3 million in 2024, then plummeted by 55.82% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, -$1.8 million for Q2 2025, and $231000.0 during Q1 2025.